Cylembio plus pembrolizumab achieved a clinically relevant 19.4 months median progression free survival (mPFS) compared to 11.0 months mPFS with pembrolizumab alone; study narrowly missed progression ...
Bricker, D. , Alberto, J. , Pecar, Z. , Pecar, D. and Asad, S. (2025) Acute Metabolic and Neurocognitive Adaptations to Short-Term Fasting. Food and Nutrition Sciences, 16, 1489-1501. doi: 10.4236/fns ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈